Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Fineline Cube May 8, 2026
Company Deals

Bio-Thera Solutions Expands License Deal with SteinCares for Latin American Market

Fineline Cube Dec 17, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced the addition of a third biosimilar to its...

Company Drug

European CHMP Supports Conditional Approval of MSD’s Welireg for VHL Disease and RCC

Fineline Cube Dec 16, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the European Medicines Agency’s Committee...

Company Drug

EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment

Fineline Cube Dec 16, 2024

Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...

Policy / Regulatory

Guangdong Province Releases List of Urgent Clinical Drugs and Devices for GBA Cities

Fineline Cube Dec 16, 2024

The medical products administration and health commission of Guangdong province have released a list of...

Company Drug

Sanofi’s Tolebrutinib Earns FDA Breakthrough Designation for Non-Relapsing Secondary Progressive MS

Fineline Cube Dec 16, 2024

Sanofi (NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted...

Company Medical Device

Roche’s cobas 6800/8800 Systems 2.0 Earn CE Certification, Set for US Market Entry

Fineline Cube Dec 16, 2024

Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0...

Company Drug

ARS Pharmaceuticals’ Neffy Receives Market Filings in Asia-Pacific Region

Fineline Cube Dec 16, 2024

US-based ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has announced that market filings for its intranasal epinephrine...

Company Drug

Fujian Cosunter Pharmaceutical’s GST-HG141 Earns Breakthrough Designation for Chronic Hepatitis B

Fineline Cube Dec 16, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Beijing Conference Outlines 2025 Healthcare Security Goals and 2024 Progress

Fineline Cube Dec 16, 2024

A national conference on healthcare security was recently held in Beijing, reviewing the achievements of...

Company Deals

Quantum Hi-Tech (ChemPartner) Plans to Raise Over RMB 930 Million in Private Placement

Fineline Cube Dec 16, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), is poised to raise...

Company Deals

AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline

Fineline Cube Dec 16, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...

Company Deals

iFlytek’s Xunfei Healthcare Passes HKEX Hearing for AI-Powered Medical IPO

Fineline Cube Dec 16, 2024

Xunfei Healthcare Technology Co., Ltd., a subsidiary of China’s leading information technology company iFlytek Co.,...

Company Deals

Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China

Fineline Cube Dec 16, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement...

Company Drug

Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101

Fineline Cube Dec 16, 2024

Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...

Company Drug

EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease

Fineline Cube Dec 16, 2024

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...

Company Drug

Wepon Medical’s WP107 for Myasthenia Gravis Accepted for FDA Review

Fineline Cube Dec 16, 2024

Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced that the US Food and...

Company Deals

Mabwell Bioscience Plans Secondary Listing in Hong Kong, Secures Funding for Bone Health Project

Fineline Cube Dec 16, 2024

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) is set to make a secondary listing on...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial

Fineline Cube Dec 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has obtained approval from...

Company Deals

Neusoft Medical Systems and Xiamen University Launch MRI R&D Center Partnership

Fineline Cube Dec 16, 2024

Neusoft Medical Systems Co., Ltd, a prominent Chinese medical technology company, has signed an agreement...

Company Deals

Neusoft Medical Systems and NMPA Collaborate on AI-Enhanced Drug Administration

Fineline Cube Dec 16, 2024

Neusoft Medical Systems Co., Ltd, a leading Chinese medical technology company, has announced a strategic...

Posts pagination

1 … 241 242 243 … 662

Recent updates

  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
  • Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength
  • Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion
  • Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Company

Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth

Company

Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength

Company

Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.